Dopamine D3 receptor antagonists as therapeutic agents.
The behavioral and pathophysiological role of the dopamine D(3) receptor, which was deduced from anatomical, lesion and drug treatment studies in the ten years following cloning of the receptor, indicated that its functions differed from those of the D(2) receptor. There is increasingly strong evidence that D(3) receptor antagonists will be effective antipsychotic agents. In this regard, an amelioration of the negative and cognitive symptoms of schizophrenia holds the most promise for D(3) receptor antagonists, a concept currently under clinical evaluation. In addition, D(3) receptors could be involved in behavioral sensitization and the potential application of D(3) receptor antagonists in the treatment of drug abuse is undergoing intensive experimental investigation.
T.H. Christopher Center for Parkinson's Disease, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, 85351, USA. Jeff.Joyce@sunhealth.org
Jeffrey N
JN
Joyce
Mark J
MJ
Millan
D000818:Animals; D018492:Dopamine Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D015394:Molecular Structure; D009570:Nitriles / Q000627:therapeutic use; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors* / Q000502:physiology; D019966:Substance-Related Disorders / Q000503:physiopathology / Q000517:prevention & control; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use
D018492:Dopamine Antagonists; D009570:Nitriles; D050637:Receptors, Dopamine D3; C409982:SB 277011; D044005:Tetrahydroisoquinolines